Observational studyJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society2021
Clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis: An international observational study.
Observational study in Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 2 syntheses or guidelines pooled it, 78 citations in OpenAlex.
- Risk factors for severe COVID-19 in people with cystic fibrosis: A systematic review.Frontiers in pediatrics · 2022Pooled it
- Systematic review: cystic fibrosis in the SARS-CoV-2/COVID-19 pandemic.BMC pulmonary medicine · 2021Pooled it
- Cystic Fibrosis Mortality Trends 1999-2024-A CDC Wonder Study.Advances in respiratory medicine · 2026Article
- Immune-metabolic trajectories delineate subgroups in paediatric long COVID.Nature communications · 2026Article
- Uncomplicated SARS-CoV-2 Infections with Preserved Lung Function in Pediatric Patients with Cystic Fibrosis: A Three-Year Single-Centre Experience.Journal of clinical medicine · 2025Article
- COVID-19 in Children With Severe Lung Disease-A Tertiary Center Cohort Study in Denmark.Pediatric pulmonology · 2025Article
- Mild and moderate manifestations of SARS-CoV-2 infection, including hospitalization, in children and adolescents with cystic fibrosis.Einstein (Sao Paulo, Brazil) · 2025Article
- Success of the German Cystic Fibrosis Registry.Pharmacoepidemiology and drug safety · 2025Article
- Clinical Outcomes Following SARS-CoV-2 Infection in Pediatric Cystic Fibrosis Patients.Cureus · 2024Article
- Beyond Borders of the Cell: How Extracellular Vesicles Shape COVID-19 for People with Cystic Fibrosis.International journal of molecular sciences · 2024Review
- Chest Physiotherapy Interventions for Children During SARS-COV-2 Pandemic.Clinical pediatrics · 2024Review
- Occurrence of COVID-19 in cystic fibrosis patients: a review.Frontiers in microbiology · 2024Review
- Mechanisms by which the cystic fibrosis transmembrane conductance regulator may influence SARS-CoV-2 infection and COVID-19 disease severity.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2023Article
- Severity of SARS-CoV-2 infection in a hospital population: a clinical comparison across age groups.Italian journal of pediatrics · 2023Article
- An Ethical Analysis Regarding the COVID-19 Pandemic Impact on Oral Healthcare in Patients with Mental Disorders.Healthcare (Basel, Switzerland) · 2023Review
- Seroprevalence and clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis.Pediatric pulmonology · 2023Article
- Epidemiological Profile of Hospitalized Patients with Cystic Fibrosis in Brazil Due to Severe Acute Respiratory Infection during the COVID-19 Pandemic and a Systematic Review of Worldwide COVID-19 in Those with Cystic Fibrosis.Healthcare (Basel, Switzerland) · 2023Article
- COVID-19 and pediatric pulmonology: Feedback from an expert center after the first year of the pandemic.Pediatric pulmonology · 2023Review
- Urine-based multi-omic comparative analysis of COVID-19 and bacterial sepsis-induced ARDS.Molecular medicine (Cambridge, Mass.) · 2023Article
- Crosslink between SARS-CoV-2 replication and cystic fibrosis hallmarks.Frontiers in microbiology · 2023Review
Corrections and comments
- Commented on by
Authors and funding
27 authors at 20 institutions in 13 countries.
Funding
Abstract
backgroundThe presence of co-morbidities, including underlying respiratory problems, has been identified as a risk factor for severe COVID-19 disease. Information on the clinical course of SARS-CoV-2 infection in children with cystic fibrosis (CF) is limited, yet vital to provide accurate advice for children with CF, their families, caregivers and clinical teams.
methodsCases of SARS-CoV-2 infection in children with CF aged less than 18 years were collated by the CF Registry Global Harmonization Group across 13 countries between 1 February and 7 August 2020.
resultsData on 105 children were collated and analysed. Median age of cases was ten years (interquartile range 6-15), 54% were male and median percentage predicted forced expiratory volume in one second was 94% (interquartile range 79-104). The majority (71%) of children were managed in the community during their COVID-19 illness. Out of 24 children admitted to hospital, six required supplementary oxygen and two non-invasive ventilation. Around half were prescribed antibiotics, five children received antiviral treatments, four azithromycin and one additional corticosteroids. Children that were hospitalised had lower lung function and reduced body mass index Z-scores. One child died six weeks after testing positive for SARS-CoV-2 following a deterioration that was not attributed to COVID-19 disease.
conclusionsSARS-CoV-2 infection in children with CF is usually associated with a mild illness in those who do not have pre-existing severe lung disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.